Adam Rosenberg

Adam Rosenberg is the Chairman of the Board at VectorY Therapeutics, a biotechnology company focused on developing innovative gene therapies. He has an extensive background in the biotech industry, with over 20 years of experience in leadership roles.

Professional Background

• Previous Leadership Roles: Adam has served as the Chair of the Board at Seamless Therapeutics and Ambagon Therapeutics. He was also the founding CEO of Aliada Therapeutics, Athenen Therapeutics (which merged with Eliem Therapeutics), and Sionna Therapeutics. Additionally, he held the position of President and CEO at Rodin Therapeutics until its acquisition in 2019.12
• Focus Areas: His career has been centered around developing therapies for neurodegenerative diseases and advancing biotechnology companies through various stages of growth.34

Current Role at VectorY

Adam Rosenberg's appointment as Chair at VectorY demonstrates the company's commitment to advancing its groundbreaking therapies. His leadership is expected to guide the strategic direction of the company as it continues to innovate in the field of gene therapy.45